Trillium Group

Omni-ID Ltd. is a developer and supplier of passive ultra high frequency radio frequency identification (RFID) technology products, specializing in low-profile tags that perform reliably in challenging environments, including on metals and liquids. Founded in 2007 and based in Farnham, United Kingdom, the company offers a range of products such as the Max, Flex, Prox, and ProVIEW tags. These products cater to various applications including asset tracking in information technology, manufacturing, and retail sectors, as well as tool tracking and industrial device management. Omni-ID's technology ensures precise identification and management of high-value assets, making it a key player in the industrial Internet of Things and RFID markets.

Omni-ID Ltd. is a developer and supplier of passive ultra high frequency radio frequency identification (RFID) technology products, specializing in low-profile tags that perform reliably in challenging environments, including on metals and liquids. Founded in 2007 and based in Farnham, United Kingdom, the company offers a range of products such as the Max, Flex, Prox, and ProVIEW tags. These products cater to various applications including asset tracking in information technology, manufacturing, and retail sectors, as well as tool tracking and industrial device management. Omni-ID's technology ensures precise identification and management of high-value assets, making it a key player in the industrial Internet of Things and RFID markets.

OyaGen, Inc. is a biotechnology company based in Rochester, New York, founded in 2003. The company specializes in the discovery, development, and commercialization of innovative pharmaceutical therapies utilizing RNA and DNA editing enzymes. OyaGen's platform technology focuses on harnessing these editing enzymes to influence a variety of biological functions, including antiviral responses, cancer treatment, immunoglobulin gene rearrangements, inflammation, ion channel activity, LDL reduction, neuro-cognitive functions, and red blood cell expression in fetal liver. Through its research, OyaGen aims to develop novel therapies that enable enhanced treatment options for conditions such as human immunodeficiency virus.

ClearMomentum, Inc. is a provider of financial reporting software tailored for venture capital and private equity investors, boards, and limited partners. Founded in 2005 and located in Canandaigua, New York, the company developed a comprehensive portfolio management solution designed to streamline the collection, analysis, reporting, and distribution of portfolio company data. ClearMomentum's offerings include ClearFinancials, a portfolio monitoring application that collects and synthesizes financial statements, and a web portal that enhances collaboration through customized workflows and document sharing. Additionally, the company provides an iPad application for monitoring key financial metrics and facilitating real-time updates among users. ClearMomentum's tools aim to improve data transparency, accuracy, and timeliness, addressing challenges such as compliance and fundraising due diligence in the alternative asset industry. With a robust data warehousing service, the company ensures that disparate portfolio documents are securely archived and easily accessed, transforming untidy data into invaluable insights for clients ranging from global buyout firms to early-stage venture capitalists.

iCardiac Technologies, Inc. is a specialized provider of cardiac safety biomarkers, focused on enhancing the efficiency of drug development programs. Founded in 2006 and headquartered in Rochester, New York, the company offers a range of services including ECG analysis, statistical reporting, and regulatory interface, all aimed at assessing the cardiac safety profile of drugs in clinical trials. Its flagship product, Dynamic QTbtbsm, comprises ECG-based cardiac safety markers that set new standards for precision and accuracy in human drug trials. iCardiac serves pharmaceutical, biotechnology, and medical device companies by ensuring that clinical trials are conducted with the utmost rigor, helping to appropriately include or exclude study subjects based on cardiac safety considerations.

Communication Synergy Technologies Inc., a Rochester, N.Y.–based developer of document management solutions.

Appairent Technologies, Inc. is a wireless multimedia systems and solutions company that provides radio modules, software and intellectual property to major consumer-electronics manufacturers. Their products - based on industry standards - employ cutting-edge technology to deliver low-power and low-cost streaming multimedia applications, from digital cameras and personal data assistants, to televisions, set-top boxes, MP3 players, laptop computers, digital camcorders and more. Appairent Technologies was formed - and is operated - by experienced consumer-electronics experts, including leaders of the IEEE 802.15 working group and an original co-founder of the 802.11 working group. They're proud to be a member of the IEEE-standards activities and a founding member of the WiMedia Alliance. Appairent Technologies spun off as an independent company from Eastman Kodak Company in January 2002.

VirtualScopics, Inc. specializes in providing imaging services for the pharmaceutical, biotechnology, and medical device industries during clinical trials. Founded in 1988 and headquartered in Rochester, New York, the company offers a range of image analysis software tools and applications that facilitate the detection and measurement of specific anatomical structures and metabolic activity through medical imaging. Their proprietary software and algorithms are designed to enhance clinical research and development by enabling accurate and reproducible measurements of subtle changes in anatomical structures associated with oncology, cardiology, neurology, and musculoskeletal diseases. VirtualScopics has established strategic alliances with several organizations to deliver integrated clinical development and medical imaging solutions tailored for various therapeutic areas and to mitigate risks in clinical studies, particularly in the Asia-Pacific region. As of May 2016, VirtualScopics operates as a subsidiary of BioTelemetry, Inc.